Introducing BrightMEMTM.
A novel treatment for Epithelial Defects and Limbal Stem Cell Deficiency.

What is BrightMEMTM?

BrightMEMTM? is a durable and optically clear basement membrane with proliferative proteins. It forms a new foundation for the ocular surface, protecting the stroma from degradation and promoting regeneration of the corneal epithelium.

What is Brightstar Therapeutics?

Brightstar Therapeutics is a biotechnology company focused on providing innovative treatment options that improve the quality of life for people living with corneal and ocular surface diseases. Brightstar Therapeutics is the first company to offer a long-term solution for improving the ocular surface through its advanced corneal allograft, BrightMEMTM.

How does it work?

BrightMEMTM expresses proteins that stimulate limbal stem cell growth while resisting degradation. In preclinical studies, BrightMEMTM supported limbal stem cell expansion and maintained a population of stem cells in the basal corneal epithelium. Clinically, up to this point, there have been no instances where the corneal epithelium failed to regenerate when treated with BrightMEMTM. BrightMEMTM offers hope as a durable solution for patients with severe corneal.

Getting started with BrightMEMTM

Saving Sight is a primary investor in Brightstar Therapeutics, and is proud to offer this innovative service to our physician partners. Connect with our Client Services team to order BrightMEMTM for your upcoming anterior keratoplasty needs.

Ready to Get Started?

Our Client Services team is happy to speak with you about your needs!

You might also be interested in...